X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
KRAZATI (adagrasib), a highly selective and potent oral small-molecule inhibitor of KRASG12C, is being evaluated in combination with cetuximab for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Lead Product(s): Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
PCM-075 (onvansertib) is a PLK-1 inhibitor, which is being evaluated in combination with Folfiri & Bevacizumab for the treatment of second-line RAS-mutated metastatic colorectal cancer.
Lead Product(s): Onvansertib,Cetuximab,Bevacizumab
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Krazati (adagrasib) is highly selective and potent oral small-molecule inhibitor of KRA SG12C. It is being evaluated for treatment of patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab,BMS-986466
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $34.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 07, 2023
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2023
Details:
SOT101 (nanrilkefusp alfa) is an IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.
Lead Product(s): Nanrilkefusp Alfa,Cetuximab
Therapeutic Area: Oncology Product Name: SOT101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated for colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Under the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of an investigational, potential first-in-class radioenhancer NBTXR3 (hafnium oxide), currently being evaluated in several studies across solid tumor indications.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $3,610.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement July 10, 2023
Details:
Braftovi (Encorafenib) Is An Oral Small Molecule Braf Kinase Inhibitor And Combination With Cetuximab Used for Patients With Patients With Braf V600E Alterations In Metastatic Colorectal Cancer.
Lead Product(s): Encorafenib,Cetuximab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
ERAS-007 is an oral ERK1/2 inhibitor. ERAS-007 + EC was generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) at all combination doses tested for the treatment of metastatic BRAF V600E- colorectal cancer.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Under the collaboration, Innovent will conduct a Phase 1b study to evaluate the anti-tumor activity and safety of the combination therapy of IBI351 (GFH925) with cetuximab in Chinese patients with advanced or metastatic NSCLC harboring KRASG12C mutation.
Lead Product(s): GFH925,Cetuximab
Therapeutic Area: Oncology Product Name: IBI351
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2023
Details:
Through collaboration, Lupin with Enzene will launch enz-124 (cetuximab) in India, the 1st biosimilar developed for Cetuximab, sold under the brand Erbitux. Cetuximab, a chimeric monoclonal antibody, is used as a targeted therapy for metastatic colorectal cancer and SCCHN.
Lead Product(s): Cetuximab
Therapeutic Area: Oncology Product Name: enz-124
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 30, 2023
Details:
IBI351 (GFH925) is a novel, orally active, potent KRASG12C inhibitor targets GTP/GDP exchange, by modifying cysteine residue of KRASG12C protein. IBI351 effectively inhibits the downstream signal pathway to induce tumor cells’ apoptosis and cell cycle arrest.
Lead Product(s): IBI351,Cetuximab
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Under the collaboration, Hummingbird will evaluate its potentially best-in-class HER3-targeting antibody, HMBD-001, in combination with SoC chemotherapy with or without Merck's cetuximab, anti-EGFR mAb, in patients with sqNSCLC in a Phase 1b clinical trial.
Lead Product(s): HMBD-001,Cetuximab
Therapeutic Area: Oncology Product Name: HMBD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2023
Details:
GFH925 inhibits the GTP/GDP exchange, an essential step in pathway activation. Subsequently, GFH925 inhibits the downstream signal pathway to induce tumor cells' apoptosis and cell cycle arrest. Being developed for advanced NSCLC patients harboring KRASG12C mutation.
Lead Product(s): GFH925,Cetuximab
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
SOT101 (nanrilkefusp alfa) is a subcutaneously administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.
Lead Product(s): Nanrilkefusp Alfa,Cetuximab
Therapeutic Area: Oncology Product Name: SO-C101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
NBTXR3 (hafnium oxide nanoparticles) is a novel, potentially first-in-class oncology product that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
By covalently and irreversibly modifying the cysteine residue of KRAS G12C protein, GFH925 inhibits the GTP/GDP exchange, an essential step in pathway activation.
Lead Product(s): GFH925,Cetuximab
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 19, 2022
Details:
The agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2022
Details:
Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).
Lead Product(s): ZN-C3,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2022
Details:
JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors.
Lead Product(s): JAB-21822,Cetuximab
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2022
Details:
23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
ALX148 (evorpacept) has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
Lead Product(s): Evorpacept,Pembrolizumab,Cetuximab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
Lead Product(s): Monalizumab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
The abstract suggests that BBT-176, a novel, 4th generation EGFR-TKI that inhibits the signaling pathway of EGFR with C797S-containing triple mutations has shown its capability of inducing clinical tumor responses in EGFR triple mutation-containing patients.
Lead Product(s): BBT-176,Cetuximab
Therapeutic Area: Oncology Product Name: BBT-176
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
Under the terms of the agreement, Lilly will provide cetuximab clinical drug supply in the U.S. and Canada for AVEO’s potential registrational study, which will assess AV-299 (ficlatuzumab) with cetuximab in HPV negative R/M HNSCC.
Lead Product(s): Ficlatuzumab,Cetuximab
Therapeutic Area: Oncology Product Name: AV-299
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aveo Oncology
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 22, 2022
Details:
Data from study in 12 evaluable patients with stage 4 disease showed that combining NBTXR3 (hafnium oxide) with concurrent chemoradiation was feasible, had a favorable safety profile, produced a 100% disease control rate, and an ORR of 58.3%.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
At its latest presentation to investors, Bridge Biotherapeutics shared interim Phase 1 study data of BBT-176 in advanced NSCLC showing that drug candidate was well-tolerated and demonstrated efficacy against EGFR-mutation positive NSCLC.
Lead Product(s): BBT-176,Cetuximab
Therapeutic Area: Oncology Product Name: BBT-176
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway), developed in partnership with Boehringer in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination with ezabenlimab (PD-1 antagonist); ongoing expansion Phase 1.
Lead Product(s): OSE-172,Ezabenlimab,Cetuximab
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $1,352.0 million Upfront Cash: $18.4 million
Deal Type: Collaboration May 03, 2022
Details:
NBTXR3 (hafnium oxide), is a novel, potentially first-in-class oncology product, composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
BND-22 (SAR444881), a novel immune checkpoint inhibitor targeting the Immunoglobulin-like transcript receptor 2 or ILT2, enhances anti-tumor activity of T cells and NK cells.
Lead Product(s): BND-22,Pembrolizumab,Cetuximab
Therapeutic Area: Oncology Product Name: BND-22
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
JAB-21822, first KRAS G12C inhibitor in combination with cetuximab, has shown preliminary efficacy in patients with colorectal cancer in global clinical trials, completed the first patient dosing, also has progressed rapidly since it submitted IND.
Lead Product(s): JAB-21822,Cetuximab
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Peking University Cancer Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Details:
Jacobio's preclinical study shows that the combination therapy of JAB-21822 and Cetuximab can enhance the anti-tumor activity of JAB-21822 inhibitors in colorectal cancer tumor models, make tumor regression, and delay tumor re-growth after the cessation of using the drug.
Lead Product(s): JAB-21822,Cetuximab
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2021
Details:
Innate to present new Phase 2 data on the combination of IPH2201 (monalizumab), a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.
Lead Product(s): Monalizumab,Cetuximab,Durvalumab
Therapeutic Area: Oncology Product Name: IPH2201
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with previously treated metastatic CRC with a BRAF V600E mutation.
Lead Product(s): Cetuximab,Binimetinib
Therapeutic Area: Oncology Product Name: Erbitux
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
ERBITUX is the first anti-EGFR antibody approved, in combination with encorafenib, for this indication and is based on results from Pfizer's BEACON CRC trial, Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAF V600E mutation.
Lead Product(s): Cetuximab,Binimetinib
Therapeutic Area: Oncology Product Name: Erbitux
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Erasca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2021
Details:
In this study, BRAFTOVI and cetuximab combination treatment group demonstrated a statistically significant extension in overall survival (OS), versus the control group (irinotecan and cetuximab based combination treatment).
Lead Product(s): Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
Details:
This alternate dosing regimen to the previously approved weekly dosing regimen allows ERBITUX infusions to be scheduled alongside other biweekly treatments, significantly reducing the frequency of patient visits to an infusion center.
Lead Product(s): Cetuximab
Therapeutic Area: Oncology Product Name: Erbitux
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
Under the terms of this agreement, NKMax will be the study sponsor, and Merck KGaA, Darmstadt, Germany will supply cetuximab for a Phase I/IIa clinical trial in NSCLC patients for weekly dosing with 250 mg/m2 cetuximab administered by intravenous injection.
Lead Product(s): Autologous natural killer cells,Cetuximab,Gemcitabine
Therapeutic Area: Oncology Product Name: SNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: NKMax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2021
Details:
BBT-176, a novel epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is designed to inhibit the signaling pathway of EGFR with C797S mutations, which arises due to osimertinib (Tagrisso)-resistant mutations in NSCLC.
Lead Product(s): BBT-176,Cetuximab
Therapeutic Area: Oncology Product Name: BBT-176
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2021
Details:
Monalizumab, Innate’s lead partnered asset. On April 24, 2015, Innate signed a co development and commercialization agreement with AstraZeneca to accelerate and broaden the development of monalizumab.
Lead Product(s): Monalizumab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 23, 2020
Details:
Under the terms of the deal, Biodesix will continue to fund 50% of the ongoing HNSCC Phase 2 trial of ficlatuzumab, and will be entitled to a low double digit royalty on any future product sales as well as 25% of future licensing revenue, subject to certain limitations.
Lead Product(s): Ficlatuzumab,Cetuximab
Therapeutic Area: Oncology Product Name: AV-299
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biodesix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 08, 2020
Details:
Under the terms of the agreement, Strata Oncology will identify patients with advanced solid tumors who have a KRAS G12C mutation and meet other eligibility criteria, to be considered for enrollment into Mirati's Phase 1/2 study, MRTX849-001 a G12C selective inhibitor.
Lead Product(s): Adagrasib,Pembrolizumab,Cetuximab
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 13, 2020
Details:
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer.
Lead Product(s): NT219,Cetuximab
Therapeutic Area: Oncology Product Name: NT219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.
Lead Product(s): MEN1611,Cetuximab
Therapeutic Area: Oncology Product Name: MEN1611
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Details:
The companies are collaborating for a clinical trial program to investigate the efficacy & safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head & neck.
Lead Product(s): Toripalimab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
Details:
Darolutamide significantly reduced risk of death by 31% in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE).
Lead Product(s): Monalizumab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Phase 3 BEACON CRC trial data showed that BRAFTOVI in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and reduced the risk of death by 40%.
Lead Product(s): Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
